徕博科(LH)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

LH 徕博科

盘前交易 11-11 06:51:01 EST

370.88

-0.95

-0.26%

最高372.69	最低363.19	成交量51.04万
今开370.04	昨收371.83	日振幅2.55%
总市值300.04亿	流通市值300.04亿	总股本8,090万
成交额1.89亿	换手率0.63%	流通股本8,090万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"LH","market":"US","secType":"STK","nameCN":"徕博科","latestPrice":370.88,"timestamp":1794344400000,"preClose":371.83,"halted":0,"volume":510426,"delay":0,"changeRate":-0.0025549310168625143,"floatShares":80900000,"shares":80900000,"eps":12.179544,"marketStatus":"盘前交易","change":-0.95,"latestTime":"11-11 06:51:01 EST","open":370.04,"high":372.69,"low":363.19,"amount":188934490.1556,"amplitude":0.025549,"askPrice":374,"askSize":1,"bidPrice":369,"bidSize":1,"shortable":3,"etf":0,"ttmEps":12.179544,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1794407400000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":672379200000,"exchange":"NYSE","adjPreClose":370.88,"dividendRate":0.007765,"postHourTrading":{"tag":"盘后","latestPrice":370.88,"preClose":370.88,"latestTime":"19:50 EST","volume":48095,"amount":17837536.69,"timestamp":1794358232588,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.6878915687702398,"impliedVol":0.2726,"impliedVolPercentile":0.504},"requestUrl":"/m/hq/s/LH","defaultTab":"news","newsList":[{"id":"2678275499","title":"徕博科（LH）盘中扬升9.33% 三季度营收增至38.1亿美元超预期并上调全年指引","url":"https://stock-news.laohu8.com/highlight/detail?id=2678275499","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678275499?lang=zh_cn&edition=full","pubTime":"2026-10-28 22:21","pubTimestamp":1793197295,"startTime":"0","endTime":"0","summary":"金吾财讯 | 徕博科（LH）盘中股价扬升9.33%，最新报362.03美元，成交额9075.86万美元。消息面上，该公司公布2026年第三季度，实现营收38.1亿美元，同比增长6.9%，高于市场预期的35.6亿美元。期内，股东应占利润约2.63亿美元，较去年同期的2.61亿美元小幅上涨，但变动不大。稀释每股收益3.22美元，较去年同期的3.12美元增长3.3%；调整后每股收益4.78美元，同比增长14.5%。公司同步上调全年业绩指引，预计收入增长区间为5.9%至6.7%，在中值水平上提升50个百分点；调整后每股收益区间为18.30至18.70美元；中值较此前上调18美分。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250107/N2NlYWIzMDQ5MjY5YzU0NWM0NDMwZTE4ZDQ3MjY3ODIxNTA5MDg=.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/N2NlYWIzMDQ5MjY5YzU0NWM0NDMwZTE4ZDQ3MjY3ODIxNTA5MDg=.png"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"307729","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181902806","title":"异动解读｜徕博科盘中上涨8.4%，财报超预期且全年指引获上调","url":"https://stock-news.laohu8.com/highlight/detail?id=1181902806","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1181902806?lang=zh_cn&edition=full","pubTime":"2026-10-28 22:00","pubTimestamp":1793196037,"startTime":"0","endTime":"0","summary":"10月28日，徕博科盘中上涨8.4%，报358.49美元/股，成交额6475.53万美元。消息面上，公司第三季度业绩与收入均超市场预期，并再次上调全年调整后每股收益与营收指引，成为股价走强的直接催化。随后机构将目标价上调至340美元，进一步强化市场积极预期。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"徕博科财报超预期，全年指引获上调","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187845206","title":"财报前瞻 | 徕博科本季度营收预计增5.62%，机构观点偏积极","url":"https://stock-news.laohu8.com/highlight/detail?id=1187845206","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1187845206?lang=zh_cn&edition=full","pubTime":"2026-10-21 09:31","pubTimestamp":1792546290,"startTime":"0","endTime":"0","summary":"徕博科将于2026年10月28日盘前发布新季度财报，市场当前更关注收入动能与利润质量的匹配以及关键新品与并购对订单结构的带动。市场一致预期本季度徕博科营收为37.59亿美元，同比增5.62%；调整后每股收益为4.66美元，同比增12.61%；息税前利润为5.56亿美元，同比增11.73%；公司上季度财报未披露对本季度的明确毛利率或净利率指引，市场一致预期层面亦未见明确口径。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"财报前瞻 | 徕博科本季度营收预计增5.62%，机构观点偏积极","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188000667","title":"徕博科在2026年投资者日强调推动持续增长与股东价值的战略优先事项","url":"https://stock-news.laohu8.com/highlight/detail?id=1188000667","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1188000667?lang=zh_cn&edition=full","pubTime":"2026-09-10 19:01","pubTimestamp":1789038071,"startTime":"0","endTime":"0","summary":"徕博科（Labcorp）在2026年投资者日活动中，着重阐述了其战略优先事项，旨在驱动持久增长并提升股东价值。该公司通过一系列举措，明确了未来发展的核心路径。这些优先事项聚焦于增强核心竞争力、优化运营效率，以及深化对客户和患者的服务承诺。管理层在会上详细介绍了如何利用创新技术、扩大诊断服务范围，并强化数据驱动决策能力，以巩固市场地位。此外，徕博科还强调了资本配置策略，包括对高增长领域的投资和股东回报机制的完善，力求在动态变化的医疗健康环境中实现长期稳健的财务表现。此次投资者日传递出的信息表明，公司正致力于通过清晰的战略布局和执行力，为所有利益相关方创造可持续的价值。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4550","LU0006061336.USD","LU0048573561.USD","LU0251142724.SGD","LU0251131958.USD","LU2237438978.USD","LU0742534661.SGD","BK4588","LH","BK4196","BK4585","LU1059921491.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121225568","title":"徕博科收购Mlm Medical Labs，强化全球中心实验室与临床试验生物标志物能力","url":"https://stock-news.laohu8.com/highlight/detail?id=1121225568","media":"美股速递","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1121225568?lang=zh_cn&edition=full","pubTime":"2026-09-08 21:11","pubTimestamp":1788873105,"startTime":"0","endTime":"0","summary":"徕博科宣布完成对Mlm Medical Labs的收购，这一战略举措显著增强了其在全球中心实验室及生物标志物检测领域的服务能力，为临床试验提供更全面的支持。此次并购聚焦于扩大徕博科在关键领域的布局，尤其是针对复杂生物标志物的分析与验证。通过整合Mlm Medical Labs的专业技术，徕博科得以进一步优化其全球实验室网络，从而提升对制药及生物技术客户的项目响应速度。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0742534661.SGD","BK4585","LU1059921491.USD","LU0251142724.SGD","LU0251131958.USD","BK4196","BK4550","LU2237438978.USD","BK4588","LU0006061336.USD","LU0048573561.USD","LH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103312457","title":"徕博科推出首款获FDA批准的血液检测，助力阿尔茨海默病病理筛查覆盖初级与专科诊疗场景","url":"https://stock-news.laohu8.com/highlight/detail?id=1103312457","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1103312457?lang=zh_cn&edition=full","pubTime":"2026-08-24 19:05","pubTimestamp":1787569547,"startTime":"0","endTime":"0","summary":"徕博科宣布，将率先推出首款获得美国食品药品监督管理局（FDA）批准的血液检测产品，用于在初级保健和专科医疗环境中检测阿尔茨海默病的病理特征。\n这一里程碑式的举措，标志着阿尔茨海默病诊断方式迎来重大变革。传统上，此类检测通常局限于专科医疗机构，而如今，这一创新检测手段有望深入更广泛的临床场景，让更多患者得以在疾病早期获得关键诊断信息。\n借助这一检测，医生可在日常诊疗中更高效地识别阿尔茨海默病的潜在病理迹象，从而为患者争取宝贵的干预时间。徕博科此举，不仅拓宽了诊断工具的适用范围，也为推动精准医疗在神经退行性疾病领域的落地迈出了坚实一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1059921491.USD","LH","LU0048573561.USD","LU0251142724.SGD","BK4585","BK4588","LU0251131958.USD","BK4196","LU0742534661.SGD","LU2237438978.USD","LU0006061336.USD","BK4550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111010241","title":"徕博科高管：ACA相关调整对2026年诊断业务量约30个基点影响的假设仍然合理","url":"https://stock-news.laohu8.com/highlight/detail?id=1111010241","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1111010241?lang=zh_cn&edition=full","pubTime":"2026-07-30 21:33","pubTimestamp":1785418412,"startTime":"0","endTime":"0","summary":"徕博科（Labcorp Holdings Inc）高管在最新电话会议中表示，旗下诊断业务因《平价医疗法案》（ACA）相关调整，预计在2026年将面临约30个基点的业务量冲击。这一影响范围的假设，至今仍被视为恰当且适用。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0006061336.USD","LU0048573561.USD","LU2237438978.USD","BK4588","BK4550","LU0251131958.USD","BK4196","LU0742534661.SGD","BK4585","LU1059921491.USD","LU0251142724.SGD","LH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103497852","title":"徕博科高管：肿瘤患者所接受的检测数量远超普通患者，推高每例样本检测量——电话会议披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1103497852","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1103497852?lang=zh_cn&edition=full","pubTime":"2026-07-30 21:33","pubTimestamp":1785418388,"startTime":"0","endTime":"0","summary":"在徕博科（Labcorp Holdings Inc）的电话会议上，一位高管指出，肿瘤患者在医院治疗的漫长过程中，通常会接受比普通患者多得多的检测。具体而言，这些患者所接受的检测频次显著高于一般人群，这一趋势直接推动了公司每例样本（Accession）对应检测数量的持续攀升。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1059921491.USD","LU0742534661.SGD","BK4585","LU0048573561.USD","LU0251142724.SGD","LU0006061336.USD","BK4196","LU2237438978.USD","BK4588","LH","LU0251131958.USD","BK4550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190044926","title":"徕博科高管：专业检测业务增速持续领先常规检测，预期这一趋势有望延续","url":"https://stock-news.laohu8.com/highlight/detail?id=1190044926","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1190044926?lang=zh_cn&edition=full","pubTime":"2026-07-30 21:29","pubTimestamp":1785418189,"startTime":"0","endTime":"0","summary":"徕博科的高管在电话会议中透露，该公司的专业检测业务板块当前正以超越常规检测业务的速度实现增长，且增长的势头颇为强劲。这位高管进一步指出，基于现有态势，他们预计这一差异化趋势将在未来一段时间内得到延续。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0006061336.USD","LU0048573561.USD","BK4588","LU2237438978.USD","BK4550","LU0251131958.USD","LU0251142724.SGD","LU0742534661.SGD","LH","BK4196","BK4585","LU1059921491.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103287053","title":"异动解读 | 徕博科盘前大跌5.43%，诊断实验室部门有机增长不及预期引发担忧","url":"https://stock-news.laohu8.com/highlight/detail?id=1103287053","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1103287053?lang=zh_cn&edition=full","pubTime":"2026-07-30 20:12","pubTimestamp":1785413547,"startTime":"0","endTime":"0","summary":"徕博科今日盘前大跌5.43%，引发市场广泛关注。消息面上，尽管徕博科公布了优于预期的第二季度业绩并上调了全年利润预期，但投资者将关注点集中在其诊断实验室部门低于预期的有机增长上。竞争对手Quest Diagnostics上周公布的业绩设定了更高标准，令市场对徕博科诊断业务的表现感到失望。从整体业绩来看，徕博科第二季度总营收增长5.8%至37.3亿美元，高于预期的37.1亿美元；经调整后每股收益为4.99美元，高于预期的4.78美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["LH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166049812","title":"徕博科推出Marker by Labcorp™遗传健康检测组合，拓宽消费者对遗传性风险检测的可及性","url":"https://stock-news.laohu8.com/highlight/detail?id=1166049812","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1166049812?lang=zh_cn&edition=full","pubTime":"2026-07-27 20:03","pubTimestamp":1785153780,"startTime":"0","endTime":"0","summary":"徕博科（Labcorp Holdings Inc.）近日正式推出Marker by Labcorp™遗传健康检测组合。此举旨在显著拓展消费者对遗传性基因风险检测的获取途径。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0251131958.USD","LU0742534661.SGD","LU0048573561.USD","LU1059921491.USD","LU2237438978.USD","BK4588","LU0006061336.USD","LH","BK4585","BK4550","BK4196","LU0251142724.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193006068","title":"财报前瞻｜徕博科本季度营收预计增6.47%，机构观点偏积极","url":"https://stock-news.laohu8.com/highlight/detail?id=1193006068","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1193006068?lang=zh_cn&edition=full","pubTime":"2026-07-24 00:06","pubTimestamp":1784822810,"startTime":"0","endTime":"0","summary":"徕博科将于2026年07月30日盘前披露财报，市场关注收入增速与调整后每股收益的韧性以及产品与合作落地带来的结构性改善。一致预期显示，本季度徕博科营收预计为美元37.11亿，同比增长6.47%；调整后每股收益预计为美元4.78，同比增长14.65%。上一季度徕博科营收为美元35.38亿，同比增长5.76%；毛利率为28.66%；归属于母公司股东的净利润为美元2.78亿，净利率为7.85%；调整后每股收益为美元4.25，同比增长10.68%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜徕博科本季度营收预计增6.47%，机构观点偏积极","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650272189","title":"Labcorp(LH)宣布派发每股0.72美元普通股季度股息","url":"https://stock-news.laohu8.com/highlight/detail?id=2650272189","media":"金吾财讯","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650272189?lang=zh_cn&edition=full","pubTime":"2026-07-10 17:58","pubTimestamp":1783677490,"startTime":"0","endTime":"0","summary":"金吾财讯 | 徕博科Labcorp(LH)发布分红公告，公司董事会正式批准最新一期普通股季度现金分红，每股派发 0.72 美元。本次分红确权日设定为 2026 年 8 月 28 日收盘，凡当日登记在册的全体普通股股东均可享有分红权益，实际现金发放时间定于 9 月 11 日。分析人士对此指出，Labcorp 持续维持稳定季度分红标准，反映管理层对中长期全球诊疗、医药研发需求保持乐观，现金流储备足以平衡研发投入、股东分红两大资金需求。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250107/NjQzZWIwYjMxODE0NDMwMmFiMWMzYWFhZmVlYWI3MGY0MzQwNTkyOTA0MzE=.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/NjQzZWIwYjMxODE0NDMwMmFiMWMzYWFhZmVlYWI3MGY0MzQwNTkyOTA0MzE=.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"302437","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0006061336.USD","LU0048573561.USD","BK4588","LU2237438978.USD","BK4550","LU0251131958.USD","LU0251142724.SGD","LU0742534661.SGD","UUP","UDN","VIG","LH","BK4196","BK4585","LU1059921491.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191592188","title":"徕博科宣布全美上市首款FDA批准基于RNA的居家结直肠癌筛查产品Colosense®","url":"https://stock-news.laohu8.com/highlight/detail?id=1191592188","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1191592188?lang=zh_cn&edition=full","pubTime":"2026-06-22 19:01","pubTimestamp":1782126100,"startTime":"0","endTime":"0","summary":"徕博科（Labcorp）宣布，其首款获得美国食品药品监督管理局（FDA）批准的基于RNA技术的居家结直肠癌筛查检测产品Colosense®，现已在美国全国范围内上市。这款创新的非侵入性检测工具，标志着结直肠癌早期筛查领域的一次重要突破，为公众提供了更为便捷、私密的筛查选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4550","LU0251131958.USD","BK4585","BK4588","LU0048573561.USD","LU2237438978.USD","LU0006061336.USD","LU0251142724.SGD","LH","LU0742534661.SGD","BK4196","LU1059921491.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145365971","title":"Genfit携手Labcorp推出Nashnext®：基于Nis4®无创诊断技术，助力识别高危MASH患者","url":"https://stock-news.laohu8.com/highlight/detail?id=1145365971","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1145365971?lang=zh_cn&edition=full","pubTime":"2026-06-09 00:00","pubTimestamp":1780934421,"startTime":"0","endTime":"0","summary":"Genfit公司宣布，其基于自主研发的非侵入性诊断技术Nis4®所打造的Nashnext®检测方案，现已通过Labcorp（徕博科）的Ondemand服务正式推出。该产品旨在帮助识别存在代谢功能障碍相关脂肪性肝炎（MASH）风险的患者。\n此项合作标志着Genfit创新的无创诊断技术在临床可及性方面迈出了重要一步。通过Labcorp广泛的检测服务网络，医疗专业人员能够更便捷地利用Nashnext®，对高危人群进行早期筛查与风险评估，从而有望实现更及时的患者管理和干预。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0251142724.SGD","BK4196","BK4550","LU0742534661.SGD","BK4585","BK4588","LU0006061336.USD","LH","LU0251131958.USD","LU0048573561.USD","LU1059921491.USD","LU2237438978.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639102624","title":"Labcorp(LH)与肿瘤临床试验联盟达成全美战略合作 扩大结直肠癌基因检测范围","url":"https://stock-news.laohu8.com/highlight/detail?id=2639102624","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2639102624?lang=zh_cn&edition=full","pubTime":"2026-05-29 19:29","pubTimestamp":1780054196,"startTime":"0","endTime":"0","summary":"Labcorp将作为独家基因检测提供商，全面支持一项针对新确诊结直肠癌患者及其高危亲属的全国性、多中心大型临床试验。作为本项全国性试验的独家技术支持方，Labcorp将依托其旗下的Invitae基因检测平台，凭借其覆盖全美的实验室网络规模和深厚的伴随诊断学术积累，为所有参与机构提供高质量的生殖系基因检测与多基因联合检测服务。","market":"us","thumbnail":"https://static.szfiu.com/news/20250107/YjU2YzAxODc0YzFlOTM1Nzk3MTU1NDIzZDRjODY4MTE1MzM5MTg2.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/YjU2YzAxODc0YzFlOTM1Nzk3MTU1NDIzZDRjODY4MTE1MzM5MTg2.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"300983","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0048573561.USD","BK4585","LU2237438978.USD","LU1059921491.USD","LU0742534661.SGD","BK4588","BK4196","LU0006061336.USD","LH","BK4550","LU0251142724.SGD","LU0251131958.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169430590","title":"徕博科推出Mylabcorp™：一款AI驱动的移动应用，助力用户解读检验报告与追踪长期健康趋势","url":"https://stock-news.laohu8.com/highlight/detail?id=1169430590","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1169430590?lang=zh_cn&edition=full","pubTime":"2026-05-20 19:01","pubTimestamp":1779274893,"startTime":"0","endTime":"0","summary":"徕博科（Labcorp）近日正式发布了一款名为Mylabcorp™的全新移动应用程序。该应用由人工智能技术驱动，旨在帮助消费者更清晰地理解实验室检验结果，并长期追踪个人健康趋势的变化。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4550","LH","LU0048573561.USD","LU0251131958.USD","LU2237438978.USD","BK4585","LU0006061336.USD","BK4588","LU0251142724.SGD","LU0742534661.SGD","LU1059921491.USD","BK4196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510472920","title":"徕博科2024财年实现净利润7.46亿美元，同比增加96.83%","url":"https://stock-news.laohu8.com/highlight/detail?id=2510472920","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2510472920?lang=zh_cn&edition=full","pubTime":"2025-02-10 00:00","pubTimestamp":1739116854,"startTime":"0","endTime":"0","summary":"2月10日，徕博科公布财报，公告显示公司2024财年净利润为7.46亿美元，同比增加96.83%；其中营业收入为130.09亿美元，同比增加6.96%，每股基本收益为8.89美元。从资产负债表来看，徕博科总负债103.13亿美元，其中短期债务11.85亿美元，资产负债比为1.79，流动比率为1.45。机构评级：截至2025年2月10日，当前有16家机构对徕博科目标价做出预测，其中目标均价为271.81美元，其中最低目标价为240.00美元，最高目标价为293.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250210000129abc86720&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250210000129abc86720&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509777981","title":"巴克莱：维持Labcorp Holdings(LH.US)评级，由持股观望调整至持股观望评级, 目标价由271.00美元调整至260.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2509777981","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2509777981?lang=zh_cn&edition=full","pubTime":"2025-02-08 06:27","pubTimestamp":1738967224,"startTime":"0","endTime":"0","summary":"巴克莱：维持Labcorp Holdings(LH.US)评级，由持股观望调整至持股观望评级, 目标价由271.00美元调整至260.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/08062748031987.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509773590","title":"杰富瑞投资银行：维持Labcorp Holdings(LH.US)评级，由买入调整至买入评级, 目标价由275.00美元调整至290.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2509773590","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2509773590?lang=zh_cn&edition=full","pubTime":"2025-02-07 07:26","pubTimestamp":1738884368,"startTime":"0","endTime":"0","summary":"杰富瑞投资银行：维持Labcorp Holdings(LH.US)评级，由买入调整至买入评级, 目标价由275.00美元调整至290.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/07072648003359.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LH"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.labcorp.com","stockEarnings":[{"period":"1week","weight":0.0479},{"period":"1month","weight":0.1881},{"period":"3month","weight":0.1465},{"period":"6month","weight":0.46},{"period":"1year","weight":0.4203},{"period":"ytd","weight":0.4783}],"compareEarnings":[{"period":"1week","weight":-0.0059},{"period":"1month","weight":-0.0368},{"period":"3month","weight":-0.0292},{"period":"6month","weight":0.0023},{"period":"1year","weight":0.1005},{"period":"ytd","weight":0.0997}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Labcorp Holdings Inc.是特拉华州的一家公司，成立于1971年。公司是一家领先的全球生命科学公司，已在指导患者护理方面深入整合。公司通过其LabCorp诊断（LCD）和Covance药物开发（CDD）部门提供全面的临床实验室和端到端药物开发服务。LabCorp定位于研究和护理交付的融合，以实现更精确和个性化的医疗保健，将世界一流的诊断和药物开发能力结合在一起。","yearOnYearQuotes":[{"month":1,"riseRate":0.645161,"avgChangeRate":0.026972},{"month":2,"riseRate":0.612903,"avgChangeRate":0.024969},{"month":3,"riseRate":0.612903,"avgChangeRate":-0.00762},{"month":4,"riseRate":0.677419,"avgChangeRate":0.052186},{"month":5,"riseRate":0.516129,"avgChangeRate":0.00838},{"month":6,"riseRate":0.59375,"avgChangeRate":0.027065},{"month":7,"riseRate":0.5,"avgChangeRate":0.011975},{"month":8,"riseRate":0.46875,"avgChangeRate":-0.026932},{"month":9,"riseRate":0.4375,"avgChangeRate":-0.00589},{"month":10,"riseRate":0.5625,"avgChangeRate":0.002175},{"month":11,"riseRate":0.6875,"avgChangeRate":0.009181},{"month":12,"riseRate":0.709677,"avgChangeRate":0.014463}],"exchange":"NYSE","name":"徕博科","nameEN":"Labcorp Holdings Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"徕博科(LH)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供徕博科(LH)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"徕博科,LH,徕博科股票,徕博科股票老虎,徕博科股票老虎国际,徕博科行情,徕博科股票行情,徕博科股价,徕博科股市,徕博科股票价格,徕博科股票交易,徕博科股票购买,徕博科股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"徕博科(LH)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供徕博科(LH)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}